Core Insights - Hi-View Resources Inc. has identified high-impact drill targets at its Golden Stranger Project following a detailed structural interpretation [1][3] - The 2025 exploration program has defined multiple high-priority epithermal and copper-gold-silver targets within the Golden Stranger corridor [2][3] Structural Data Interpretation - The 2025 field structural mapping identified two dominant directions for veining at 103°/65° and 347°/55°, with jointing at 309°/70° and 351°/52° [4] - The main shear and orientation of a mineralized rhyolite dyke is 350°/51-56°, with secondary structures oriented at 309°/70° [4] - Historical drilling shows zones of high and low-grade intersections along the targeted primary fault direction, indicating mineralization concentration along antithetic fault sets [4] Drilling Plans and Targets - Nine preliminary drill holes are planned to test the main Golden Stranger mineralized corridor and new copper-gold anomalies identified during the 2025 fieldwork [5] - The Main Zone hosts semi-continuous mineralization over a 270-meter strike, averaging 4–7 meters true width to a depth of 80 meters, with historical trenching results including 6.9 meters grading 8.31 g/t Au [5][11] - The 2025 Copper Zone surface anomaly extends 330 meters by 70 meters, with samples showing grades up to 3.72% Cu, 2.42 g/t Au, and 1,400 ppm Ag [5][17] Future Exploration - Proposed drilling will target both primary and secondary structures at optimal angles to intersect high-grade ore shoots [5][19] - Additional 3D IP, magnetic, and VLF inversion modeling will refine drill collar placement and prioritize targets for the 2026 field season [20]

Core Insights - Nevis Brands Inc. has launched Major™ 100mg cannabis-infused shots in New Mexico, expanding its market presence and catering to consumer demand for convenient cannabis options [2][3] - The company plans to re-enter the Arizona market by the end of November 2025, leveraging previous demand and new production partnerships [3][4] - Major™ products have sold over 5 million bottles since their launch in Washington State in 2019, indicating strong market acceptance [1] Product Details - Major™ shots are dosable 100mg THC beverages that provide effects within 10-20 minutes, designed for on-the-go consumption [1][2] - The shots are available in three flavors: Blueberry, Fruit Punch, and Blackberry Lemonade [4] Company Strategy - The launch in New Mexico is part of a broader multi-state growth strategy, with expectations of success based on past performance in Arizona from 2021-2024 [4] - Nevis Brands aims to build a portfolio of iconic recreational cannabis brands, focusing on premium and approachable products [5]

Group 1 - Andina Copper Corporation issued 7,550,000 shares at $0.40 per share, raising gross proceeds of $3,020,000 through a private placement [1] - The company paid a total of $24,000 in finder's fees related to the offering [1] Group 2 - Andina Copper Corporation is focused on copper exploration in South America and is listed on the Canadian Stock Exchange, Frankfurt, and OTC exchanges [2] - The company holds two significant copper discoveries in the Andean porphyry belt located in Argentina and Colombia, along with an undrilled copper-gold target in Chile's Coastal Cordillera [3]

Core Insights - Inflection Resources Ltd. has successfully completed the acquisition of the Endurance Projects, a significant portfolio of copper-gold projects in Australia's Northern Territory, enhancing its exploration strategy [2][6][37] Project Overview - The Endurance Projects consist of twelve exploration licenses covering a total area of 4,592 km², strategically located near a major geological structure that may localize IOCG copper-gold mineralization [3][6] - The licenses include sixteen principal target areas characterized by geophysical anomalies similar to those found at major IOCG deposits like Ernest Henry and Olympic Dam [4][6] Geological Context - The area is covered by younger rocks and alluvium, with thickness ranging from 60 to 170 m, which has historically hindered exploration efforts [5][6] - Modern exploration techniques, including high-resolution geophysical surveys, are now being employed to test these concealed targets effectively [5][6] Target Areas - The Bigeye target is identified as the highest priority, defined by an 8 km × 8 km aeromagnetic high and associated with a Bouguer gravity anomaly, indicating potential for IOCG-style mineralization [10][14] - The Barreleye target is characterized by a 2.5 km × 0.5 km magnetic high, suggesting a dense magnetic center and potential for sulphide accumulation [16] Exploration Strategy - The company is prioritizing target assessment through data compilation and engagement with Aboriginal stakeholders, applying a mineral systems approach to maximize exploration potential [2][6] - A program of first-pass air-core drilling is planned for the first half of the following year, aimed at testing the identified targets [31] IOCG Deposit Significance - IOCG deposits are among the most metal-rich mineral systems globally, with significant examples in Australia, including Olympic Dam and Ernest Henry, which serve as exploration models for the Endurance Projects [32][33] - The potential for large-scale IOCG deposits in the Endurance Projects is underscored by the favorable geological and geophysical characteristics observed [6][32]

Core Viewpoint - Credissential Inc. is unable to file its annual financial statements by the deadline due to audit delays, resulting in a Management Cease Trade Order being granted [1][2]. Group 1: Audit Delays - The delay in completing the audit is attributed to the complexity of the financial reporting period, which involved consolidating two acquisitions and convertible note financings [2]. - Additional audit procedures were required for purchase price allocations, fair value assessments, and financial instrument accounting, extending beyond the initial timeline [2]. Group 2: Filing Expectations - The Company expects to file the Annual Filings on or before November 29, 2025, and will announce the completion through a news release [3]. - In the meantime, the Company will issue bi-weekly default status reports as per the alternative information guidelines during the MCTO [3]. Group 3: Management Cease Trade Order (MCTO) - During the MCTO, the general investing public can continue to trade the Company's common shares, but the CFO and CEO are prohibited from trading until the Annual Filings are submitted [4]. - The Company confirms it is not subject to any insolvency proceedings and has disclosed all material information regarding its affairs [5][9].

Core Viewpoint - Plaid Technologies Inc. has successfully closed the second tranche of its non-brokered private placement, raising a total of $976,000 from both tranches combined, which will be used to support various operational and developmental activities [1][2][3]. Fundraising Details - The second tranche consisted of 100,000 common shares issued at $1.25 per share, generating $125,000 in proceeds [1]. - Together with the first tranche closed on October 24, 2025, the total gross proceeds from the Offering amount to $976,000 [2]. Use of Funds - The net proceeds from the Offering will supplement previously disclosed allocations in the Company's Listing Statement dated August 13, 2025. The breakdown of fund usage is as follows: - Sales & Marketing: Originally $45,000, now $50,000 additional - Management and Consulting Fees: Originally $80,000, now $30,000 additional - General & Administrative Expenses: Originally $50,000, now $25,000 additional - Development Fees: Originally $170,000, now $50,000 additional - Unallocated Working Capital: Originally $10,000, now $821,000 additional - Total: Originally $355,000, now $976,000 total raised [3][10]. Company Overview - Plaid Technologies focuses on developing and commercializing graphene-enhanced technology, particularly a proprietary graphene-infused concrete mixture aimed at applications in wellbore cement and subsurface projects [4]. - The management anticipates that this unique mixture will revolutionize well abandonment processes by integrating advanced materials with precise engineering [4].

Core Viewpoint - Voyageur Pharmaceuticals Ltd. has signed a Non-Exclusive Distribution Agreement with Phalanx to expand its market presence in Mexico's healthcare sector, particularly in barium-based contrast media products [1][2][4]. Company Overview - Voyageur Pharmaceuticals is a Canadian public company focused on developing cost-effective imaging contrast media products, specifically barium and iodine Active Pharmaceutical Ingredients (API) [8]. - The company aims to become a key player in the contrast media market by vertically integrating its production processes, ensuring quality and cost efficiency [11]. Partnership Details - The agreement with Phalanx represents a strategic partnership aimed at driving market expansion into Mexico, with Phalanx responsible for registering and distributing Voyageur's products [2][4]. - Phalanx is a leading pharmaceutical distributor in Mexico with over 20 years of experience in the health sector, providing market entry strategies and ensuring regulatory compliance [3][5]. Market Strategy - This partnership is a significant milestone in Voyageur's international growth strategy, targeting underserved markets with increasing demand for high-quality contrast media [4]. - The sales of Voyageur's products in Mexico will depend on local regulatory approval processes, with Phalanx leading the necessary filings [4]. Operational Focus - Voyageur's Frances Creek Project is central to its business plan, aiming to produce high-quality barium sulfate contrast media that can replace less effective synthetic products currently dominating the market [10]. - The company is committed to responsible sourcing and manufacturing practices, encapsulated in its motto "From the Earth to the Bottle" [11].

Core Viewpoint - Blackbird Critical Metals Corp. has received conditional approval from the Canadian Securities Exchange for its acquisition of Lir Life Science Inc. and the listing of the resulting issuer's common shares upon completion of the acquisition [1][11]. Acquisition Details - The company will acquire 100% of Lir Life Sciences' common shares in exchange for issuing 22,312,678 common shares of Blackbird on a post-consolidation basis to Lir shareholders [3]. - Following the acquisition, the business will continue under the name "Lir Life Sciences Corp." [3]. Share Consolidation - Prior to the acquisition closing, Blackbird will consolidate its shares on a 1.5:1 basis, reducing the number of outstanding shares from approximately 7,762,912 to about 5,175,275 [4][5]. - Registered shareholders will receive instructions for exchanging their existing certificates for post-consolidation shares [6]. Financial Transactions - The acquisition includes a transaction fee of 2% of the acquisition value, payable in 379,000 Resulting Issuer Shares [8]. - Lir Life Sciences has completed a private placement of 3,050,270 subscription receipts at $0.35 each, raising approximately $1.07 million, which will convert into Lir Shares prior to closing [9]. - Lir Life Sciences has settled $109,343 in debt by issuing 312,408 Lir Shares at a deemed price of $0.35, which will also convert into Resulting Issuer Shares upon closing [10]. Trading and Regulatory Approval - Trading in Blackbird Shares will remain halted until all conditions for listing are satisfied, including the completion of the acquisition and final approval from the CSE [11]. - The new CUSIP and ISIN numbers for the post-consolidation shares will be 50206C100 and CA50206C1005, respectively [7].

Core Insights - Argenta Silver Corp. has successfully completed its first year of operations, establishing a strong team and gaining recognition in the market [6][20] - The company aims to become a leading silver producer in Latin America, focusing on exploration and production across multiple operations [8] - Significant financial backing has been secured, with C$35 million raised, of which only C$12 million has been spent on operations and acquisitions [10] Company History and Development - The acquisition of the El Quevar Project was finalized on October 24, 2024, marking a pivotal moment for Argenta Silver [2][20] - The company has built a culturally diverse team and established a reputation for transparency and results, attracting major institutional investors [6][9] - The CEO, Joaquin Marias, has a background in geology and has been involved in the El Quevar project since 2010 [3][4] Financial Performance and Capital Allocation - Argenta Silver raised C$15.3 million through a private placement to capitalize the company, with significant investments from notable shareholders [2][10] - The company plans to allocate approximately 40% of its upcoming capital expenditure towards resource expansion and 60% towards exploration [14] Exploration and Technical Achievements - The company has conducted extensive geological work, including re-logging 29,000 meters of historical drill core and detailed mapping of 133 km² [10] - Recent drilling results have shown high silver grades, with surface results exceeding 20,000 g/t Ag and notable drill intercepts of 1.05 meters at 18,467 g/t Ag [18] - The foundational mineral resource estimate of the Yaxtché deposit includes an indicated resource of 45.3 million ounces of silver at a grade of 482 g/t Ag [21] Future Plans and Vision - Argenta Silver is set to embark on a larger drilling campaign, planning 12,000 to 15,000 meters of drilling and geophysical surveys in previously unexplored areas [13][14] - The company aims to unlock the potential of the El Quevar project, which has been dormant for ten years under previous management [16] - The strategic approach focuses on balancing resource area drilling with exploration to maximize value and uncover new deposits [17]

Core Viewpoint - Helix BioPharma Corp. reported a net loss of $5,205,000 for the fiscal year ended July 31, 2025, showing an improvement from a loss of $9,264,000 in the previous year, indicating progress in financial management and operational focus [2][13]. Financial Performance - The total comprehensive loss for the year was $5,205,000, translating to a loss of $0.09 per common share, compared to a loss of $0.21 per common share in the previous year [2][13]. - Research and Development expenses decreased by 40% to $3,558,000 from $5,977,000 in the previous year, attributed to the conclusion of a Phase Ib/II study and changes in stock-based compensation [8][9]. - Operating, general, and administration expenses also saw a significant reduction of 43%, totaling $1,839,000 compared to $3,262,000 in the prior year, primarily due to changes in service providers [10][11]. Clinical Development - The Phase Ib/II trial (LDOS006) for metastatic pancreatic adenocarcinoma was completed in October 2024, with ongoing data analysis and a Clinical Study Report expected in fall 2025 [3]. - A new Phase Ib/Randomized Phase II study (LDOS007) is in planning to assess L-DOS47 in combination with pembrolizumab for NSCLC, with positive feedback received from the FDA regarding the study design [4][6]. Corporate Development - The company decided to focus on developing L-DOS47 as a combination therapy for NSCLC, terminating collaborations with external research institutions that did not align with this focus [6]. - The company closed its laboratory in Edmonton, Canada, on October 31, 2024, and liquidated laboratory equipment while securing important documents and samples [6]. Capital and Liquidity - As of July 31, 2025, the company reported a working capital deficiency of $2,807,000 and an accumulated deficit of $215,876,000, indicating challenges in liquidity [13][18]. - The company closed a non-brokered private placement of 2,222,333 common shares at $0.75 per share, raising gross proceeds of $1,667,000 [7]. Research & Development Focus - The company’s pipeline includes L-DOS47, which targets CEACAM6-expressing tumors, and two pre-IND candidates: LEUMUNA™ and GEMCEDA™, aimed at addressing significant unmet medical needs in oncology [20].